Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
28 studies found for:    DPYD
Show Display Options
Rank Status Study
1 Completed Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
Condition: Breast Cancer
Intervention: Procedure: Phlebotomy
2 Completed Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
Condition: Neoplasms
Intervention: Drug: Capecitabine, 5-fluorouracil
3 Recruiting Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
Condition: Neoplasms
Intervention: Drug: Fluoropyrimidine (capecitabine or 5-fluorouracil)
4 Completed Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
Condition: Colorectal Cancer
Interventions: Other: 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype;   Other: Therapeutic drug monitoring of 5FU
5 Active, not recruiting Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity
Condition: Drug Safety Biomarkers
Intervention: Other: Test meal (breakfast)
6 Completed A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
Condition: Neoplasms
Intervention: Drug: ADH300004
7 Recruiting Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer
Condition: Gastrointestinal Cancer
Intervention: Drug: S-1 plus oxaliplatin
8 Unknown  Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines
Conditions: Colorectal Cancer;   Intravenous 5 Fluorouracile
Intervention: Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
9 Completed Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: eniluracil;   Procedure: conventional colon surgery
10 Completed Predicting Response to Capecitabine in Women With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Completed A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
Condition: Tumors
Interventions: Drug: S-1;   Drug: FT
12 Recruiting PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions
Condition: Adverse Drug Reaction
Intervention: Other: Pharmacogenomic testing
13 Suspended A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
Condition: Neoplasms
Intervention: Drug: ADH300004
14 Terminated A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: ADH300004
15 Unknown  Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
Condition: Gastric Cancer
16 Unknown  Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
Condition: Pancreatic Cancer
Interventions: Drug: S-1;   Drug: S-1 plus Leucovorin
17 Unknown  Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
Conditions: Gastric Cancer;   Esophageal Cancer;   Pancreatic Cancer;   Colon Cancer
Intervention: Drug: S-1
18 Not yet recruiting Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoadjuvant Therapy
Interventions: Drug: S-1;   Drug: 5-FU
19 Completed Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: TOMOX;   Drug: Bevacizumab
20 Unknown  A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Irinotecan;   Drug: Cisplatin;   Drug: TS-1 (S-1)

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.